Cargando…

TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis

The morbidity and mortality of lung cancer rank the first among all kinds of cancer. In China, anaplastic lymphoma kinase-positive pulmonary tumors account for nearly 5% of non-small cell lung cancer (NSCLC), and these patients are quite likely to develop brain metastases, as high as around 45%. Alt...

Descripción completa

Detalles Bibliográficos
Autores principales: Qin, Jiqiu, Li, Ru, Ma, Hong, Ding, Peng, Yang, Qin, Hu, Lilai, Wu, Deliu, Xiong, Shaoquan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662799/
https://www.ncbi.nlm.nih.gov/pubmed/37478272
http://dx.doi.org/10.1097/MD.0000000000034138
_version_ 1785138275773579264
author Qin, Jiqiu
Li, Ru
Ma, Hong
Ding, Peng
Yang, Qin
Hu, Lilai
Wu, Deliu
Xiong, Shaoquan
author_facet Qin, Jiqiu
Li, Ru
Ma, Hong
Ding, Peng
Yang, Qin
Hu, Lilai
Wu, Deliu
Xiong, Shaoquan
author_sort Qin, Jiqiu
collection PubMed
description The morbidity and mortality of lung cancer rank the first among all kinds of cancer. In China, anaplastic lymphoma kinase-positive pulmonary tumors account for nearly 5% of non-small cell lung cancer (NSCLC), and these patients are quite likely to develop brain metastases, as high as around 45%. Although anaplastic lymphoma kinase-tyrosine kinase inhibitors crizotinib and alectinib have proved effective for controlling tumor metastases to the brain, drug resistance and disease progression cannot be ignored in the course of treatment. PATIENT CONCERNS: Most of the literature reports that traditional Chinese medicine (TCM) has produced satisfactory results in the treatment of cancer patients as an adjuvant treatment for various malignancies in a 53-year-old male patient who developed advanced NSCLC with brain metastases. As first-line crizotinib and erlotinib treatments were ineffective and the intracranial lesions progressed extensively, the patient chose to receive TCM treatment alone in the hope of prolonging his life and improving his quality of life. DIAGNOSES: A 53-year-old male patient who developed advanced NSCLC with brain metastasis. Because first-line crizotinib and alectinib have failed, and the intracranial lesions progressed in a large area. INTERVENTIONS: The patient requested that the final therapeutic strategy be Chinese medicine as monotherapy for long-term treatment. The patient took 30 mL of the decoction 1 hour after a meal, 3 times a day. The patient was not treated with dehydrating agents or diuretics during the TCM treatment. OUTCOMES: The improvement was obvious after 3 months of treatment, and significant reduction of cranial lesions. During the follow-up period, the patient developed neither severe liver damage nor kidney damage. LESSONS: This case is the first 1 in the world where TCM was introduced as monotherapy for severe conditions with extensive brain metastases and achieved remarkable efficacy.
format Online
Article
Text
id pubmed-10662799
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-106627992023-07-21 TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis Qin, Jiqiu Li, Ru Ma, Hong Ding, Peng Yang, Qin Hu, Lilai Wu, Deliu Xiong, Shaoquan Medicine (Baltimore) 5700 The morbidity and mortality of lung cancer rank the first among all kinds of cancer. In China, anaplastic lymphoma kinase-positive pulmonary tumors account for nearly 5% of non-small cell lung cancer (NSCLC), and these patients are quite likely to develop brain metastases, as high as around 45%. Although anaplastic lymphoma kinase-tyrosine kinase inhibitors crizotinib and alectinib have proved effective for controlling tumor metastases to the brain, drug resistance and disease progression cannot be ignored in the course of treatment. PATIENT CONCERNS: Most of the literature reports that traditional Chinese medicine (TCM) has produced satisfactory results in the treatment of cancer patients as an adjuvant treatment for various malignancies in a 53-year-old male patient who developed advanced NSCLC with brain metastases. As first-line crizotinib and erlotinib treatments were ineffective and the intracranial lesions progressed extensively, the patient chose to receive TCM treatment alone in the hope of prolonging his life and improving his quality of life. DIAGNOSES: A 53-year-old male patient who developed advanced NSCLC with brain metastasis. Because first-line crizotinib and alectinib have failed, and the intracranial lesions progressed in a large area. INTERVENTIONS: The patient requested that the final therapeutic strategy be Chinese medicine as monotherapy for long-term treatment. The patient took 30 mL of the decoction 1 hour after a meal, 3 times a day. The patient was not treated with dehydrating agents or diuretics during the TCM treatment. OUTCOMES: The improvement was obvious after 3 months of treatment, and significant reduction of cranial lesions. During the follow-up period, the patient developed neither severe liver damage nor kidney damage. LESSONS: This case is the first 1 in the world where TCM was introduced as monotherapy for severe conditions with extensive brain metastases and achieved remarkable efficacy. Lippincott Williams & Wilkins 2023-07-21 /pmc/articles/PMC10662799/ /pubmed/37478272 http://dx.doi.org/10.1097/MD.0000000000034138 Text en Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY) (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle 5700
Qin, Jiqiu
Li, Ru
Ma, Hong
Ding, Peng
Yang, Qin
Hu, Lilai
Wu, Deliu
Xiong, Shaoquan
TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
title TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
title_full TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
title_fullStr TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
title_full_unstemmed TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
title_short TCM monotherapy achieves significant efficacy in crizotinib-refractory advanced NSCLC with brain metastasis
title_sort tcm monotherapy achieves significant efficacy in crizotinib-refractory advanced nsclc with brain metastasis
topic 5700
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10662799/
https://www.ncbi.nlm.nih.gov/pubmed/37478272
http://dx.doi.org/10.1097/MD.0000000000034138
work_keys_str_mv AT qinjiqiu tcmmonotherapyachievessignificantefficacyincrizotinibrefractoryadvancednsclcwithbrainmetastasis
AT liru tcmmonotherapyachievessignificantefficacyincrizotinibrefractoryadvancednsclcwithbrainmetastasis
AT mahong tcmmonotherapyachievessignificantefficacyincrizotinibrefractoryadvancednsclcwithbrainmetastasis
AT dingpeng tcmmonotherapyachievessignificantefficacyincrizotinibrefractoryadvancednsclcwithbrainmetastasis
AT yangqin tcmmonotherapyachievessignificantefficacyincrizotinibrefractoryadvancednsclcwithbrainmetastasis
AT hulilai tcmmonotherapyachievessignificantefficacyincrizotinibrefractoryadvancednsclcwithbrainmetastasis
AT wudeliu tcmmonotherapyachievessignificantefficacyincrizotinibrefractoryadvancednsclcwithbrainmetastasis
AT xiongshaoquan tcmmonotherapyachievessignificantefficacyincrizotinibrefractoryadvancednsclcwithbrainmetastasis